Literature DB >> 286623

Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia.

S Al-Ismail, J A Whittaker.   

Abstract

The ratio of the pre-ejection period to the left ventricular ejection time (PEP:LVET) was measured in two groups of patients with acute myeloblastic leukaemia (AML) receiving the anthracycline antibiotic doxorubicin (DXR). Patients receiving high doses of DXR per course (about 90 mg/m2) showed a significant increase in the PEP:LVET ratio irrespective of the total cumulative dose. At a lower dose per course (less than 50mg/m2) only patients who had a total cumulative dose of over 450 mg/m2 showed significant increases in ratio. ECG changes were seen in both groups of patients but did not correlate significantly with the dosage. These findings, which suggest that DXR cardiotoxicity is schedule dependent, are important in the design of schedules of DXR for treating cancer and in interpreting the changes in systolic time intervals (STIs) observed with different schedules. Measurement of the STI is a simple and convenient method of assessing DXR cardiotoxicity. While a total DXR dose of 550 mg/m2 should not normally be exceeded, by carefully monitoring the STI the recommended total dose may be exceeded safely in selected patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 286623      PMCID: PMC1598901          DOI: 10.1136/bmj.1.6175.1392

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  16 in total

1.  A critical review of the systolic time intervals.

Authors:  R P Lewis; S E Rittogers; W F Froester; H Boudoulas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

2.  Anthracycline cardiotoxicity and acute myelogenous leukaemia.

Authors:  S A Al-Ismail; D H Parry; J A Whittaker
Journal:  Br Med J       Date:  1977-03-26

Review 3.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

4.  A clinicopathologic analysis of adriamycin cardiotoxicity.

Authors:  E A Lefrak; J Pitha; S Rosenheim; J A Gottlieb
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

5.  Adriamycin cardiotoxicity in man.

Authors:  J J Rinehart; R P Lewis; S P Balcerzak
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

6.  Cardiotoxicity of adriamycin and related anthracyclines.

Authors:  L Lenaz; J A Page
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

7.  Developmental therapy in adult acute leukemia.

Authors:  E J Freireich; G P Bodey; K B McCredie; E M Hersh; E A Gehan; J Hart; J U Gutterman; V Rodriguez; T Smith; J P Hester
Journal:  Arch Intern Med       Date:  1976-12

8.  Systolic time interval to predict doxorubicin cardiotoxicity.

Authors:  S A Al-Ismail; J A Whittaker
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

9.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity.

Authors:  A J Weiss; R W Manthel
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

10.  Dose response evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; L H Baker; J E Gottlieb; S E Rivkin; S P Balcerzak; G N Grumet; S E Salmon; T E Moon; B Hoogstraten
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

View more
  5 in total

1.  Hemodynamic effects of chronic 4'epi-adriamycin administration.

Authors:  J Milei; J J Ale; G Garay; F Otero; A Z Comba; H O Gugliotta; R A Storino
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 2.  Systolic time intervals: a review of the method in the non-invasive investigation of cardiac function in health, disease and clinical pharmacology.

Authors:  S Hassan; P Turner
Journal:  Postgrad Med J       Date:  1983-07       Impact factor: 2.401

3.  Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.

Authors:  J A Whittaker; S A Al-Ismail
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

Review 4.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

5.  Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.

Authors:  M Miyagawa; S Tanada; K Hamamoto
Journal:  Eur J Nucl Med       Date:  1991
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.